Allergic sensitization to pegylated interferon-α results in drug eruptions

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 7, 2015, Pages 775-783

  Meller, S ^a   Gerber, P A ^a   Kislat, A ^a   Hevezi, P ^a,b   Gobel T ^c,d   Wiesner, U ^a   Kellermann, S ^a   Bunemann E ^a   Zlotnik, A ^b   Haussinger D ^c   Erhardt, A ^c   Homey, B ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Orthopedic Surgery   (Germany)

^d Petrus Krankenhaus   (Germany)

Author keywords

chemokines; drug eruption; lymphocyte activation test; maculopapular exanthema; pegylated Interferon

Indexed keywords

PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; CYTOKINE; INTERFERON REGULATORY FACTOR; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG ERUPTION; DRUG SENSITIZATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; INTRACUTANEOUS TEST; MALE; PATCH TEST; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; T LYMPHOCYTE ACTIVATION; TH2 CELL; COMPLICATION; DRUG ERUPTIONS; GENE EXPRESSION; GENETICS; HEPATITIS C, CHRONIC; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SKIN; SKIN TEST; T LYMPHOCYTE SUBPOPULATION;

ANTIVIRAL AGENTS; CYTOKINES; DRUG ERUPTIONS; GENE EXPRESSION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SKIN; SKIN TESTS; T-LYMPHOCYTE SUBSETS;

EID: 84931570851     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12618     Document Type: Article

References (35)

1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH,. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.
2. Cohen J,. The scientific challenge of hepatitis C. Science 1999; 285: 26-30.
3. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al., Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501-1506.
4. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al., Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
5. Youngster S, Wang YS, Grace M, Bausch J, Bordens R, Wyss DF,. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des 2002; 8: 2139-2157.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
7. Harris JM, Martin NE, Modi M,. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40: 539-551.
8. Meller S, Erhardt A, Auci A, Neumann NJ,. Homey B Drug-induced exanthema caused by pegylated interferon-alpha 2b. Hautarzt 2003; 54: 992-993.
9. Hashimoto Y, Kanto H, Itoh M,. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol 2007; 34: 577-582.
10. Veldt BJ, Schalm SW, Janssen HL,. Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon. J Clin Gastroenterol 2007; 41: 432.
11. Milkiewicz P, Yim C, Pache I, Heathcote J,. Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon. Can J Gastroenterol 2005; 19: 677-678.
12. Cottoni F, Bolognini S, Deplano A, Garrucciu G, Manzoni NE, Careddu GF, et al., Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon? Acta Derm Venereol 2004; 84: 120-123.
13. Kawada K, Maeda N, Kobayashi S, Sowa J, Tsuruta D, Kawada N,. Injection site with generalized rash caused by pegylated interferon alpha 2a injection. Dermatology 2006; 212: 82-83.
14. Tavakoli-Tabasi S, Bagree A,. A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C. J Clin Gastroenterol 2012; 46: 162-167.
15. Fried MW,. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (5 Suppl 1): S237-S244.
16. Posadas SJ, Pichler WJ,. Delayed drug hypersensitivity reactions-new concepts. Clin Exp Allergy 2007; 37: 989-999.
17. Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH,. Heparin-induced skin lesions. Lancet 2012; 380: 1867-1879.
18. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P,. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51.
19. Homey B, Wang W, Soto H, Buchanan ME, Wiesenborn A, Catron D, et al., Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol 2000; 164: 3465-3470.
20. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E, et al., Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis.PG-6621-32. J Immunol 2000; 164: 6621-6632.
21. Pivarcsi A, Muller A, Hippe A, Rieker J, van Lierop A, Steinhoff M, et al., Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A 2007; 104: 19055-19060.
22. Meller S, Winterberg F, Gilliet M, Muller A, Lauceviciute I, Rieker J, et al., Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005; 52: 1504-1516.
23. Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ,. CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy 2008; 63: 181-188.
24. Pichler WJ, Tilch J,. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59: 809-820.
25. Li Z, Ji F, Zheng Y, An J, Peng Z,. Pegylated interferon, but not conventional interferon therapy induced severe skin lesions. Ann Hepatol 2012; 11: 570-571.
26. Fernandez TD, Mayorga C, Torres MJ, Cornejo-Garcia JA, Lopez S, Chaves P, et al., Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs. Allergy 2008; 63: 712-719.
27. Tapia B, Morel E, Martin-Diaz MA, Diaz R, Alves-Ferreira J, Rubio P, et al., Up-regulation of CCL17, CCL22 and CCR4 in drug-induced maculopapular exanthema. Clin Exp Allergy 2007; 37: 704-713.
28. Tough DF, Borrow P, Sprent J,. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947-1950.
29. Fisher AA,. Immediate and delayed allergic contact reactions to polyethylene glycol. Contact Dermatitis 1978; 4: 135-138.
30. Hannuksela M, Pirila V, Salo OP,. Skin reactions to propylene glycol. Contact Dermatitis 1975; 1: 112-116.
31. Judge A, McClintock K, Phelps JR, Maclachlan I,. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006; 13: 328-337.
32. Richter AW, Akerblom E,. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 1983; 70: 124-131.
33. Richter AW, Akerblom E,. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 1984; 74: 36-39.
34. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P,. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 2012; 9: 1319-1323.
35. Shimizu T, Ichihara M, Yoshioka Y, Ishida T, Nakagawa S, Kiwada H,. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. Biol Pharm Bull 2012; 35: 1336-1342.